



How do we react on the FDA-report on alloplastic materials ?




U.S. Food and Drug Administration Protecting and Promoting Your Health

Urogynecologic Surgical Mesh: Update on the Safety and Effectiveness of Transvaginal Placement for Pelvic Organ Prolapse

July 2011







Click here versitätsmedizin IFSW

> The Bell Law Firm PLLC **Transvaginal Mesh Problems**

Linda Gross received 11,1 Million € compensation for a mesh complication



- 1	Include:		
	 Avauta Piut ** BloSynthetic Support System Avauta Solo** Synthetic Support System Fatos Subgrat Felvico S Tasue Felvico S Susue Felvico S Homen Felvico ** Polynoprove Mach Americo Hedda Systems or AHS 	BAIRD Scientific	Enter the code above: * Coder the code above: * Coder the ends displayed above the
	American Medical Systems, based in Minnesota, has two products on the market:	Johnson+Johnson	Latest Blogs
	Bevate() Anterior and Apical Prolapse Repair System	ETHICON	 Significant Milestone in the F Transvaginal Mesh Implant F
	Boston Scientific Corp., a Massachusettes based company, has been making transvaginal mesh patches for over 25 years. Its brands include		 Alternatives to Transvaginal Is Transvaginal Mesh Safe?
	 » Advantage** Sling System » Obtryx® Curved Single 		 Symptoms of Transvaginal I Surgery
	 > Obtryx® Mesh Sling > Prefyx Mid U[™] Mesh Sling System 		» What is Vaginal Mesh Erosio
- 1	» Prefyx PPS ^{**} System		




🍋 🗗 🗾 in

(877) 548-4261

Call 1.888.480.1123

I understood from my good friend Metil Itil that medicolegal problems are important in Turkey - as they are in Germany




Universitätsmedizin

There is no condition or disease that cannot be made worse by surgery !

aim of old surgeons:

- patient should survive
 patient should not have an infection
 - patient should not be worse than before surgery



What are the expectations of our patients?

Robinson et al (Kings College Hospital London)2013




57 % are happy with a 60% improvement without side effects

38 % accept a minor procedure with a 85 % success rate and a 2% risk of side effects (e.g. self catheterisation)

23 % accept a major operation with a 85 % success rate and a 2% risk of side effects (e.g. self catheterisation)



A woman's estimated lifetime risk of POP is 30-50 percent, with 2 percent of women becoming symptomatic. Symptomatic POP can be managed conservatively with either pelvic floor muscle exercises or vaginal inserts to support the prolapsing tissue (pessaries). Surgical correction is also an option, although not all women will have long-term improvement in symptoms from traditional surgical correction without mesh. In total, women have an estimated 11 percent lifetime incidence of surgery to repair POP or SUI.



Department of Health – Hospital Episode Statistics Ward & Hilton, ICS 2006



If You have a new hammer, every problem looks like a nail ! appare dangei close c How te doctor Elizabeth V

> BMJ, London WC1H 9JR Richard Smith editor rsmith@bmj.cor

BMJ 2003;326:12(



tsmedizin

lelines on

nies:

panies from the ls this funding


tors depend completely iceutical advertising, but nd heavily on such

38th ANNUAL MEETING

Dublin, Ireland May 28 - June 1, 2013



12 papers and posters discussing products taken from the market at that time !



5 000 000 implanted worldwide

TVT (Gynecare) ►LIFTTM (Cousin Biotech) Serasis[™] (Serag Wiessner) >Obtape[™] (Mentor) >Uretex[™] (Sofradim) ►MonarcTM (AMS) ►T-SlingTM (Herniamesh) Stratasis[™] (Cook) >Uratape[™] (Porges) ►I.STOPTM (CL Medical) ≻LynxTM (Boston Scientific) >Veritas[™] Collagen Matrix >Synovis >DynaMesh (FEG-textile) MiniArc (AMS)

Sabre[™] (Mentor) IVSTM (Tyco) SPARCTM (AMS) PelviLace[™] (Mentor) Tordynex[™] (Tulip) **Pro Surg-Biosling**[™] Remeex[™] (Neomedic) Safyre[™] (Promedon) **TOB[™] (Porgès)** Swing-band[™] (Text.HI-TEC) **Obtryx[™] (Boston Scientific)** Emerald[™] (Gallini) TVT-O (Gynecare) **TVT-Secur** (Gynecare) MiniArc Pro (AMS) >Adjust,Surgimesh,Aspira,Ophira, Gynemesh, Elevate....



The New 510(k) Paradigm - Alternate Approaches to Demonstrating Substantial Equivalence in Premarket Notifications

An alternative approach may be used if such approach satisfies the requirements of the applicable statute, regulations, or both.

many of the "new" slings and meshes did not have to provide any data, because they fulfilled the 510(k) conditions - apparently not !

W.Edwards Deming 1900-1993

Universitätsmedizin

"In God we trust all others bring data."

Table 2: A CLASSIFICATION OF COMPLICATIONS RELATED DIRECTLY TO THE INSERTION OF PROSTHESES (MESHES, IMPLANTS, TAPES) OR GRAFTS IN UROGYNECOLOGICAL SURGERY

CATEGORY

		post - op	T3: 24 hours to 2 weeks post – op	T4: 2 weeks to usual post - op review (6 to 12 weeks)	T5: Post - op review T6:1 to 12 months post		3yrs post - op
T1: I	ntraoperative	T2: up to 24 hours		ME (clinically diagnosed)			
	Include hematoma or systemic compromise		7A: Bleeding complication including haematoma	7B: Major degree of resuscitation or intensive care*	7C : Mortality * *(additional com - no site applical		
6 7	Skin compromise Include discharge pain lump or sinus tract formation Patient compromise		ct formation	6A: Asymptomatic, abnormal finding on clinical examination	6B: Symptomatic e.g. discharge, pain or lump	6C: Infection e.g	. sinus tract D = Abscess
5	Rectum or Bowel compromise or perforation Include prosthesis (graft) perforation and fistula			5A: Small intraoperative defect (rectal or bowel)	5B: Rectal injury or compromise	5C: Small or La or compromise	rge bowel injury
4	Urinary Tract compromise or perforation Include prosthesis (graft) perforation, fistula and calculus			4A : Small intraoperative defect e.g. bladder perforation	4B : Other lower urinary tract complication or urinary retention	4C : Ureteric or upper urinary tract complication	
3		er >1cm exposure, includ	ing extrusion	3A : Asymptomatic 1-3A <i>a</i> if mesh contraction	3B : Symptomatic 1-3B (<i>b-e</i>) if mesh contraction	2C : Infection 3C : Infection 1-3C (<i>b-e</i>) if me	D = Abscess D = Abscess sh contraction
1	Include promine penetration (with Grades of mest	pithelial separation ence (e.g. due to wrinklin thout separation) or contr h contraction (<i>a-e</i>) from 7 ller ≤ 1cm exposure	raction (shrinkage)	 A (Asymptomatic) 1A: Abnormal prosthesis or graft finding on clinical examination 2A: Asymptomatic 	B (Symptomatic) 1B: Symptomatic e.g. unusual discomfort / pain; dyspareunia (either partner); bleeding 2B: Symptomatic	C (Infection) 1C: Infection (s or actual)	

S1: Vaginal: S2: Vaginal: away from area of suture line from area of suture line

S2: Vaginal: away from from area of suture line **S3**: Vaginal Vault

S4: Trocar passage Exception: Intra-abdominal (S7)

S5: Trocar entry / exit

exit S6: other skin site

S7: Intra-abdominal

S

N.B. 1. Multiple complications may occur in the same patient. There may be early and late complications in the same patient. i.e. All complications to be listed. Tables of complications may often be procedure specific.

2. The highest final category for any single complication should be used if there is a change within time. (patient 888)

3. Urinary tract infections and functional issues (apart from 4B) have not been included.

Peter K. Sand, Evanston Continence Centre, Evanston. Illinois. U.S.A.

Universitätsmedizin

Obstetrics & Gynecology: August 2010 - Volume 116 - Issue 2, Part 1 - pp 293-303 doi: 10.1097/AOG.0b013e3181e7d7f8 Original Research

Vaginal Mesh for Prolapse: A Randomized Controlled Trial

Iglesia, Cheryl B. MD; Sokol, Andrew I. MD; Sokol, Eric R. MD; Kudish, Bela I. MD; Gutman, Robert E. MD; Peterson, Joanna L. RN; Shott, Susan PhD

Cochrane

Abstract

OBJECTIVE: To present 3-m a double-blind, multicenter rar controlled trial comparing trac prolapse surgery without mes surgery with mesh.

METHODS: Women with pelv quantification prolapse stage: randomized to vaginal colpop mesh or traditional vaginal co mesh. The primary outcome n objective treatment success (prolapse quantification stage months. Secondary outcome included quality-of-life variable complication rates. CONCLUSION: At 3 months, there is a high vaginal mesh erosion rate (15.6%) with no difference in overall objective and subjective cure rates. This study questions the value of additive synthetic polypropylene mesh for vaginal prolapse repairs.

CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, www.clinicaltrials.gov, NCT00475540.

LEVEL OF EVIDENCE: I

© 2010 The American College of Obstetricians and Gynecologists

RESULTS: Sixty-five women were recruited from January 2007 to August 2009, when the



NIHILISM

Believing in nothing can be exhausting.

500 reoperations after alloplastic slings/meshes

but

pe

Universitätsmedizin

Mesh-associated complications are not rare. The most common meshe related complication experienced by patients undergoing transvaginal POP repair with mesh is vaginal mesh rong erosion .Based on data from 110 studies including 11,785 women, approximately 10 percent of women undergoing transvaginal POP repair with mesh experienced mesh erosion para within 12 months of surgery.

OAB/opstruction


FΛ

100

150

200

つちい



Mesh contraction, causing vaginal shortening, tightening, and/or vaginal pain in association with transvaginal POP repair with mesh, is increasingly reported in the literature .

Total

28

23

51

Percentage of degradation

21.43%

47,83%

33,339

759

la

Non Deteriorated

22

12

34


Deteriorated


17



rsitätsmedizin









mesh erosions

metaanalysis: 54 studies; 7054 women

up to 12 % mesh erosions after abdominal colposacropexy

up to 21 % mesh erosions after vaginal mesh insertion

Int Urogynecol J 2010;21:1413-31

symptoms of defect healing



Int Urogynecol J (2012) 23:127-129 DOI 10.1007/s00192-011-1498-9

CASE REPORT

Partner dyspareunia—a report of six cases

Eckhard Petri · Kiran Ashok





Outsch !


dyspareunia/hispareunia after meshes

Universitätsmedizin

Withagen	2011	294	20/7	1 (28%)	12	PP		
Maher	2011	55	3/21	(14%)	24			
Long	2011	60 (Perigee TM) 48 (Prolift TM)		0 (16%) 8 (25%)	6 6			
Milani	2011	127	1/4:	(2%)	12			a starter of
Sergent	2011	101	4/52	(8%)	57			A A A A A A A A A A A A A A A A A A A
Sayer	2011	110	2/32	(6%)	24			
Jacquetin	2010	90	5/3:	(14%)	3		Cattor	
Moore	2010	87	6/6:	(9%)	24			A CONTRACT
Fayyad	2010	36	7/1	(43%)	24	Sall St	Mill So	a series
Feiner	2010	117	4/5	(8%)	12		A STATE	
Wetta	2009	50			12			Harle
Milina	2009	46	2/1	(18%)	1			
Altman	2009	69			12	12-10		
Su	2009	33			6	nace		
Lowman	2008	57	6/3	o(17%)	12 🚽	12 mar		
Hinoul	2008	48	3/2) (15%)	12			
Sentilhes	2008	83		(16%)	1 1	R.I.		J
de Tayrac	2007	143	10/	8 (12.8%)	10	Coated Pl)	No

pain after transobturator approach






pain does not disappear after 4 weeks, even not after 4 months !



pain index %



omit manuscripts: http://www.editorialmanager.com/iujo/

Universitätsmedizin

International Urogynecology Journal

Volume 22 Number 5 May 2011

Int Urogynecol J (2011) 22:505–506 DOI 10.1007/s00192-011-1407-2

EDITORIAL

To mesh or not to mesh? That is the question

Steven Swift

☑ Springer

So, how do we answer the question; to mesh or not to mesh? I strongly believe that both approaches are adequate and serve our patients well.

					A
apical pr	olaps	e - sympto	oms	K.Baessler 2012	
1.1.1 abdominal sacral colpopexy Benson 1996 6 3 Maher 2004 3 4	vs vaginal sacrospi 8 14 42 6 4 43	Risk Ratio <u>Veight M-H, Fixed, 95% Cl</u> nous colpopexy 76.3% 0.47 [0.20, 1.11] 23.7% 0.70 [0.17, 2.95] 100.0% 0.53 [0.25, 1.09]		Risk Ratio M-H, Fixed, 95% CI	
Subtotal (95% CI) 8 Total events 9 Heterogeneity: Chi² = 0.21, df = 1 (P Test for overall effect: Z = 1.72 (P = 0)	18 = 0.65); l² = 0%				
1.1.2 abdominal sacro-hysteropex Roovers 2004 16 Subtotal (95% CI) 4 Total events 16	1 5 41 1	sterectomy plus anterior and/or pos 00.0% 3.20 [1.29, 7.92] 100.0% 3.20 [1.29, 7.92]	sterior colporrhaphy at 1 year	*	And
Heterogeneity: Not applicable Test for overall effect: $Z = 2.52$ (P = 0	0.01)	sterectomy plus anterior and/or pos	sterior colporrhaphy at 8 years		
Roovers 2004 13 4	2 5 42	100.0% 2.60 [1.02, 6.85] 100.0% 2.60 [1.02, 6.65]		-	Skcrospinous
Test for overall effect: Z = 2.00 (P = 1.1.4 vaginal sacrospinous colpop		ravaginal slingplasty			Pulendal nerve
Meschia 2004a 2 3	33 3 33 33 33 3	100.0% 0.67 [0.12, 3.73] 100.0% 0.67 [0.12, 3.73]			
1.1.5 laparoscopic sacral colpope	xy vs total vaginal (oolypropylene mesh			
Maher 2011 NEW 1	53 4 55 53 55	100.0% 0.26 [0.03, 2.25] 100.0% 0.26 [0.03, 2.25]			
Total events 1 Heterogeneity: Not applicable Test for overall effect: Z = 1.23 (P =	4 0.22)				
1.1.6 uterosacral colpopexy vs va	ginal polypropylene	mesh			
lglesia 2010 NEW 3 Subtotal (95% Cl)	33 1 26	100.0% 2.36 [0.26, 21.42] 100.0% 2.36 [0.26, 21.42]			
Total events 3 Heterogeneity: Not applicable Test for overall effect: Z = 0.76 (P =	1 0.44)				

0 05 0 2

Posterior compartment Universitätsmedizin

Posterior repair with autologous tissue without insertion of a mesh has a success rate of 86% and remains a good option in the primary situation (LOE 1b).

Actually there is no reason to use non-absorbable meshes routinely in primary vaginal prolapse surgery in the posterior compartment, taking in account the higher complication rates (LOE 2).

> AWMF-guidelineregistry

Nr. 015/006



Be aware of complications !

at an averge the anatomical success rate is 10% higher with the use of synthetical mesh, but, complication rates with dyspareunia, mesh erosions and mesh contraction with pain has to be taken in account (LOE 2).

AWMF-guidelines-registry

Nr. 015/006

FDA U.S. Food and Drug Administration

Home> News & Events> Newsroom> Press Announcements

News & Events

FDA NEWS RELEASE

For Immediate Release: July 13, 2011 Media Inquiries: Karen Riley, 301-796-4674, karen.riley@fda.hhs.gov Consumer Inquiries: 888-INFO-FDA

FDA: Surgical placement of mesh to repair pelvic organ prolapse poses risks Agency says other options may expose women to less risk than transvaginal procedure

The U.S. Food and Drug Administration today issued an updated safety communication warning health care providers and patients that surgical placement of mesh through the vagina to repair pelvic organ prolapse may expose patients to greater risk than other surgical options.

reduction of recurrencies with meshes of app. 10% same incidence of reoperations – complications ! patient satisfaction identical – no advantage with meshes !



In October 2008, the FDA issued a Public Health Notification (PHN) to inform clinicians and patients of adverse events related to urogynecologic use of surgical mesh, and to provide recommendations on how to mitigate risks and how to counsel patients. Following the PHN, the FDA continued to monitor the outcomes of urogynecologic use of surgical mesh. A search of the FDA's Manufacturer and User Device Experience (MAUDE) database from the last 3 years (January 1, 2008 - December 31, 2010), identified 2,874 Medical Device Reports (MDRs) for urogynecologic surgical meshes, including reports of injury, death, and malfunctions. Among the 2,874 reports, 1,503 were associated with pelvic organ prolapse (POP) repairs, and 1,371 were associated with stress urinary incontinence (SUI) repairs.



Physicians should:

- Obtain specialized training for each mesh placement technique, and be aware of its risks.
- Be vigilant for potential adverse events from the mesh, especially erosion and infection.
- Watch for complications associated with the tools used in transvaginal placement, especially bowel, bladder and blood vessel perforations.



Physicians should:

 Inform patients that implantation of surgical mesh is permanent, and that some complications associated with the implanted mesh may require additional surgery that may or may not correct the complication. Inform patients about the potential for serious complications and their effect on quality of life, including pain during sexual intercourse, scarring, and narrowing of the vaginal wall (in POP repair).



Home

NEWS VERDICTS & SETTLEMENTS ARTICLES CONTACT US

Department of Health and Human Services

MAZIE SLATER KATZ & FREEMAN, LLC

Home MAZIE

Content on this pag

LATEST NE

FDA Public Health No.

March 2009:



COMPLICATIONS FROM GYNECARE PROLIFT AND BARD AVAULTA MESH PRODUCTS

If you have had a **Gynecare Prolift** prolene mesh or **Bard Avaulta** mesh product placed in your body for pelvic floor repair or urinary incontinence, and have suffered complications, you may have a viable product liability claim against the manufacturers of those products. Ethicon, which is a division of Johnson & Johnson manufacturers the Gynecare Prolift and C.R. Bard, Inc. manufactures the Bard Avaulta. The known complications include, but are not limited to, mesh erosion, mesh shrinkage, infection, granuloma formation, dyspareunia (pain with sexual relations) and neuropathic pain. The failure of the Gynecare Prolift and Bard Avaulta mesh products can lead to the need for multiple operations to remove the mesh, and can result in additional severe injuries such as scar tissue, neuropathic pain and urinary problems. These problems have recently been recognized by the FDA in Public Health Notifications issued in October 2008 and February 2009, in which over 1000 reports and complaints regarding mesh products were lodged.



We are currently litigating against Ethicon and Johnson & Johnson, and are expanding our litigation against C.R. Bard. If you believe that you have been seriously injured due to these products, and you are interested in learning more about how we can help, please provide the following information:

	ttltute legal advice. By providing the requested informat y a written retainer agreement between you and our lav	
Send Info		
Explanation of Complications (p	lease be detailed ;:	
Date of First Complications:	(format: mm/dd/yyyy)	
Name of Product(s) initially impl		
Date of Initial Implant Surgery:	(format: mm/dd/yyyy)	
E-mail:	Phone:	
City:	State: Choose One	Zip:
Address:		I







"The doctor is in court on Tuesdays and Wednesdays."






U.S. Food and Drug Administration Protecting and Promoting Your Health

the reaction is very variable in different countries

- in the USA meshes for prolapse repair nearly completely disappeared
- in Germany apparently only few surgeons care
- there are even new developments and products without data !



RECOMMENDATION:



It is not clear that transvaginal POP repair with mesh is more effective than traditional non-mesh repair in all patients with POP and it may expose patients to greater risk. The Safety Communication provides updated recommendations for health care providers and patients and updates the FDA's activities involving surgical mesh for the transvaginal repair of POP.

own concept

primary prolapse : native tissue repair
total prolapse : sacrospinous fixation

- recurrent prolapse : abdominal sacrocolpopexy
- paravaginal defect: colposuspension
- multiple recurrencies : mesh

April 30th - May 4th, 2014

Titanic Deluxe Hotel, Belek - Antalya

TAJEV









